Assessment of an Automatic Closed-loop Insulin Delivery System

February 9, 2017 updated by: Bruce A. Buckingham, Stanford University
The overall aim of this research proposal is to determine the safety, feasibility and efficacy of an automatic closed-loop insulin delivery system.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study will be completed in two parts.

The initial part of this study will be an inpatient evaluation of the system with the primary goal of assessing safety and feasibility. This will involve 8 subjects with type 1 diabetes, aged 14 - 40 years, admitted for up to 60 hour. Plasma glucose levels will be collected hourly and tested by YSI (YSI 2300, Yellow Springs Instrument). These studies will be performed at Stanford University and will include group sporting activities to mimic the diabetes camp environment. Capillary blood glucose testing will be performed every 2-3 hours before meals, snacks, exercise, and prebed by subjects with research staff supervision during the day and at 00:00, 03:00 and 07:00 by research staff. These data will be reviewed by the DSMB before proceeding to camp studies.

The second part of this study will be to test the efficacy of the system during diabetes summer camps. We will test the system in subjects with type 1 diabetes, aged 14-40 years, attending diabetes camp. There will be 20 subjects recruited, with 10 subjects randomized to the control arm Medtronic 530G system with threshold suspend (control group) and 10 subjects randomized to the automatic closed-loop insulin delivery (intervention group). Capillary blood glucose testing will be performed every 2-3 hours before meals, snacks, exercise and prebed by subjects with research staff supervision and at 00:00, 03:00 and 07:00 by research staff. The primary aim of this study is to generate preliminary data of system safety and efficacy in a closely supervised environment that challenges glucose control.

Study Type

Interventional

Enrollment (Actual)

21

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Angelus Oaks, California, United States, 92305
        • Camp Conrad-Chinnock
      • Mountain View, California, United States, 94040
        • Packard El Camino Hospital
      • Palo Alto, California, United States, 94304
        • Lucile Packard Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 40 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Clinical diagnosis of type 1 diabetes

    • The diagnosis of type 1 diabetes is based on the investigator's judgment
    • C peptide levels and antibody determinations are not required
  2. Daily insulin therapy for ≥ 12 months
  3. Insulin pump therapy for ≥ 3 months
  4. Age 14.0 - 40.0 years
  5. Subject comprehends written English
  6. Female subjects who are sexually active must be on acceptable method of contraception e.g. oral contraceptive pill, diaphragm, IUD
  7. Female subjects past menarche must have a negative urine pregnancy test
  8. Informed consent form is signed by the subject and/or parent and assent assigned by the subject if under 18 years of age
  9. For subjects under 18 years, both the subject and parent/guardian understand the study protocol and agree to comply with it. Both parents must sign if possible.

Exclusion Criteria:

  1. Subject has a medical disorder that in the judgment of the investigator will affect the wearing of the devices or the completion of any aspect of the protocol
  2. Diabetic ketoacidosis in the past month
  3. Hypoglycemic seizure or loss of consciousness or an event requiring glucagon or IV glucose in the past 3 months
  4. Subject has a respiratory condition such as asthma, treated with systemic or inhaled corticosteroids in the previous 6 months or cystic fibrosis
  5. Subject has a history of any cardiac or vascular disorder such as myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, arrhythmia or thromboembolic disease
  6. Subject has a history of liver or kidney disease (other than microalbuminuria)
  7. Subject has active Graves' disease
  8. Subjects with inadequately treated thyroid disease or celiac disease
  9. Subject has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
  10. Subject has a history of diagnosed medical eating disorder
  11. Subject has a history of known illicit drug abuse
  12. Subject has a history of known prescription drug abuse
  13. Subject has a history of current alcohol abuse
  14. Subject has a history of visual impairment which would not allow subject to participate
  15. Subject has an active skin condition that would affect sensor placement
  16. Subject has adhesive allergies
  17. Subjects requiring an intermediate or long-acting insulin (such as NPH, detemir or glargine)
  18. Subjects requiring other anti-diabetic medications other than insulin (oral or injectable)
  19. Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
  20. Subject is currently on beta blocker medication
  21. Subject is currently participating in another investigational study (drug or device)
  22. Subject is deemed by the investigator to be unwilling or unable to follow the protocol
  23. Presence of a febrile illness within 24 hours of enrollment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: automatic closed-loop insulin delivery
The closed-loop arm will consist of participants wearing a sensor and transmitter which transmits sensor glucose data. The algorithm determines insulin delivery rates and this is delivered in microboluses every 5 minutes
Device: Automatic closed-loop insulin delivery
Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
Active Comparator: Control
The subjects in the control arm will wear the 530G system using Enlite and MiniLink transmitter and threshold suspend.
Device: Control
Threshold suspend
Other Names:
  • 530G Pump

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety of Automatic Closed Loop Insulin Delivery System in Adolescents and Adults With Type 1 Diabetes
Time Frame: 6 days
  1. As measured by the number of events of plasma glucose values ≤ 50 mg/dL OR frequency of system alerts preceding a plasma glucose value of ≤ 50 mg/dL in all subjects
  2. As measured by the number of events of system alerts of plasma glucose values >300 mg/dL lasting for more than one hour in all subjects.
  3. As measured by number of events of serum ketones >3 mmol/L in all subjects
  4. As measured by the number of events meeting the criteria for severe hypoglycemia, defined as hypoglycemic seizure, loss of consciousness or coma or an event requiring administration of glucagon or IV glucose in all subjects
6 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of Using the Automatic Closed Loop Delivery System in Adolescents and Adults With Type 1 Diabetes
Time Frame: 6 days
  1. As measured by the system initiating and operating properly for at least 75% of the time for 75% of subjects.
  2. As measure by the completion of study enrollment procedures and education on system use within 2 hours for 75% of the subjects.
6 days
Efficacy of Hybrid Closed-loop System in Comparison With Control
Time Frame: 6 days
As measured by overall mean sensor glucose percent time in range 70-180 mg/dL.
6 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Stanford University

Collaborators

Medtronic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2014

Primary Completion (Actual)

September 1, 2014

Study Completion (Actual)

September 1, 2014

Study Registration Dates

First Submitted

June 26, 2014

First Submitted That Met QC Criteria

February 11, 2015

First Posted (Estimate)

February 19, 2015

Study Record Updates

Last Update Posted (Actual)

March 17, 2017

Last Update Submitted That Met QC Criteria

February 9, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • G140095

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 1

Clinical Trials on Automatic closed-loop insulin delivery

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe